NCT05315882 (CY-CMV-2020) is a clinical trial in CMV Infection, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud.

What condition does NCT05315882 study?

NCT05315882 studies CMV Infection.

Is NCT05315882 still recruiting?

NCT05315882 is currently completed. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT05315882: CY-CMV-2020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA

Completed Last updated 7 April 2022

What this trial tests

trial in CMV Infection in 300 participants. Completed in 17 December 2020.

Timeline

14 February 2020

Primary endpoint
17 March 2020

17 December 2020

Quick facts

Lead sponsor	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	14 February 2020
Primary completion	17 March 2020
Estimated completion	17 December 2020
Sites	1 location across Spain

Conditions studied

CMV Infection — all drugs for CMV Infection →

Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — full company profile →

Who can join

18 and older, any sex, with CMV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant cyclophosphamide as GvHD prophylaxis, using a database with information from historical clinic data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for CMV Infection

Currently open trials in the same condition.

NCT06853184 — Study Evaluating the Efficacy and Safety of Artesunate · Phase 2 · recruiting

Other Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials

Trials by the same sponsor.

NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
NCT06936501 — The Cooling Sensation Safe Deglution Study · NA · recruiting
NCT07192445 — Usability of Graphic Medicine in Psychology Education · NA · completed
NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
NCT06251232 — Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05315882 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05315882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing